跳至主要内容
临床试验/NL-OMON36044
NL-OMON36044已完成不适用

A randomized, double-blind, placebo-controlled first time into human study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of intranasal dosing with GSK2245035, a TLR7 agonist, in healthy volunteers and allergic rhinitics - GSK2245035 SAD study in HV and rhinitis patients

GlaxoSmithKline0 个研究点目标入组 75 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • healthy male volunteers
  • 18 - 55 years of age
  • BMI 19 - 29.9 kg/m2;Part 2:
  • male volunteers with a pollen allergy
  • 18 - 55 years of age
  • BMI 19 - 29.9 kg/m2
  • positive RAST test for pollen allergy

排除标准

  • - Suffering from: hepatitis B, cancer or HIV/AIDS
  • - Participation in another drug study within 3 months prior to dosing in this study
  • - Blood donation within 3 months prior to dosing in this study of donated more than 1.5 liters of blood in the 10 months prior to dosing in this study

研究者

相似试验